Sarepta Therapeutics up 6% - Plans to Acquire Manufacturing FacilityCatherine Kinney (Author) Published Date : May 29, 2014 19:13 ET
Sarepta Therapeutics (SRPT), which develops innovative RNA-based therapeutics, said it has agreed to acquire a multifunctional manufacturing facility on 26 acres of land in Massachusetts. Sarepta intends to use the facility to manufacture investigational exon skipping therapies for Duchenne muscular dystrophy. The transaction totals about $25 million in acquisition costs and planned enhancements, and is expected to close in July. SRPT trades in a 52-week range of $12.12 to $55.61.
Sarepta Therapeutics up 6% - Plans to Acquire Manufacturing Facility